Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

oncgnostics licenses MDxHealth tech
March 2015
SHARING OPTIONS:

IRVINE, Calif. & HERSTAL, Belgium—oncgnostics GmbH has received a limited worldwide license to MDxHealth SA’s methylation specific PCR (MSP) technology. Per the license agreement, MDxHealth has granted oncgnostics a limited, non-transferable, non-exclusive, worldwide license to its patented MSP technology for diagnostic applications in cervical cancer, for which it will receive upfront and milestone payments in return, as well as royalties on net sales.
 
“oncgnostics is pleased to obtain a license to MDxHealth’s proprietary epigenetic technology for use in our cervical cancer diagnostics programs. This technology allows for the accurate and sensitive assessment of DNA methylation markers included in our first test GynTect, which is intended for the early detection of cervical neoplasias that may progress to cancer,” said Dr. Alfred Hansel, CEO of oncgnostics.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.